Skip to Content

180 Life Sciences Corp Ordinary Shares ATNF

Morningstar Rating
$2.33 +0.32 (15.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ATNF is trading at a 47% discount.
Price
$2.11
Fair Value
$5.54
Uncertainty
Extreme
1-Star Price
$39.52
5-Star Price
$6.55
Economic Moat
Xjkvzpr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATNF is a good fit for your portfolio.

Trading Information

Previous Close Price
$2.01
Day Range
$1.953.00
52-Week Range
$1.8151.30
Bid/Ask
$2.31 / $2.34
Market Cap
$1.69 Mil
Volume/Avg
560,745 / 93,537

Key Statistics

Price/Earnings (Normalized)
0.42
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
5

Valuation

Metric
ATNF
Price/Earnings (Normalized)
0.42
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
ATNF

Financial Strength

Metric
ATNF
Quick Ratio
0.58
Current Ratio
0.70
Interest Coverage
−1,110.59
Quick Ratio
ATNF

Profitability

Metric
ATNF
Return on Assets (Normalized)
−9.43%
Return on Equity (Normalized)
−16.14%
Return on Invested Capital (Normalized)
−14.73%
Return on Assets
ATNF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYlypbhbxtQrxr$571.0 Bil
VRTX
Vertex Pharmaceuticals IncCyjdyxtZqjhz$107.8 Bil
REGN
Regeneron Pharmaceuticals IncLskfznmLssrqv$106.1 Bil
MRNA
Moderna IncCtjlhzqtQypp$42.3 Bil
ARGX
argenx SE ADRKqdwrjzhmJbsh$23.7 Bil
BNTX
BioNTech SE ADRVqzbsjwwqNlfz$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncVsdqczxgzDlnzll$19.4 Bil
BMRN
Biomarin Pharmaceutical IncTwzldmkyQmgml$16.7 Bil
RPRX
Royalty Pharma PLC Class AFpxbqcchXxmlx$13.6 Bil
INCY
Incyte CorpFfypjmytjQgqhdj$12.8 Bil

Sponsor Center